» Articles » PMID: 28830639

T Cell Acute Lymphoblastic Leukemia (T-ALL): New Insights into the Cellular Origins and Infiltration Mechanisms Common and Unique Among Hematologic Malignancies

Overview
Journal Blood Rev
Publisher Elsevier
Specialty Hematology
Date 2017 Aug 24
PMID 28830639
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% and 25% of total childhood and adult ALL cases, respectively. During T-ALL, patients are at risk of organ infiltration by leukemic T-cells. Infiltration is a major consequence of disease relapse and correlates with poor prognosis. Transendothelial migration of leukemic cells is required to exit the blood stream into target organs. While mechanisms of normal T-cell transmigration are well known, the mechanisms of leukemic T-cell extravasation remain elusive; but involvement of chemokines, integrins and Notch signaling play critical roles. Here, we summarize current knowledge about molecular mechanisms of leukemic T-cell infiltration with special emphasis on the newly identified subtype early T-cell-progenitor (ETP)-ALL. Furthermore, we compare the extravasation potential of T-ALL cells with that of other hematologic malignancies such as B-ALL and acute myeloid leukemia (AML).

Citing Articles

The rewired immune microenvironment in leukemia.

Ciantra Z, Paraskevopoulou V, Aifantis I Nat Immunol. 2025; 26(3):351-365.

PMID: 40021898 DOI: 10.1038/s41590-025-02096-9.


Head and Neck Classic Hodgkin, T and NK Lymphomas with Eosinophilia.

Danielson D, Aguilera N, Auerbach A Head Neck Pathol. 2025; 19(1):10.

PMID: 39873807 PMC: 11775375. DOI: 10.1007/s12105-025-01751-9.


The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis.

Liu J, An Y, Sun R, Zhang X, Guo S, Gao X Front Oncol. 2025; 14():1478888.

PMID: 39845313 PMC: 11752923. DOI: 10.3389/fonc.2024.1478888.


High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.

Calvo J, Naguibneva I, Kypraios A, Gilain F, Uzan B, Gaillard B Leukemia. 2024; 39(2):323-336.

PMID: 39580584 PMC: 11794132. DOI: 10.1038/s41375-024-02473-7.


Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.

Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T Cancer Sci. 2024; 116(2):453-461.

PMID: 39572007 PMC: 11786320. DOI: 10.1111/cas.16405.